Clinical Trials Logo

Recurrent Kaposi Sarcoma clinical trials

View clinical trials related to Recurrent Kaposi Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03077451 Recruiting - Clinical trials for Recurrent Kaposi Sarcoma

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02595866 Recruiting - HIV Infection Clinical Trials

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

Start date: February 3, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Monoclonal antibodies, such as pembrolizumab, may block tumor or cancer growth in different ways by targeting certain cells. It may also help the immune system kill cancer cells.

NCT ID: NCT02137564 Withdrawn - HIV Infection Clinical Trials

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma

Start date: July 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects, good and bad, of gamma secretase inhibitor PF-03084014 and to see how well it works in treating patients with acquired immune deficiency virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink the tumor.

NCT ID: NCT01154452 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Start date: June 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

NCT ID: NCT01057121 Active, not recruiting - Clinical trials for Recurrent Kaposi Sarcoma

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Start date: August 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT01016730 Active, not recruiting - HIV Infection Clinical Trials

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Start date: January 22, 2010
Phase: Phase 1
Study type: Interventional

This pilot, phase I trial studies the side effects and best dose of bortezomib in treating patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come back or has not responded to treatment. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00064142 Completed - Clinical trials for Recurrent Kaposi Sarcoma

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.